Analytical Data
-
Gene name
IFNw
- Application
-
Alternative Names
IFNw；Interferon omega-1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P05000
-
Expression Region
1-195aa
-
AA Sequence
MALLFPLLAA LVMTSYSPVG SLGCDLPQNH GLLSRNTLVL LHQMRRISPF LCLKDRRDFR FPQEMVKGSQ LQKAHVMSVL HEMLQQIFSL FHTERSSAAW NMTLLDQLHT GLHQQLQHLE TCLLQVVGEG ESAGAISSPA LTLRRYFQGI RVYLKEKKYS DCAWEVVRME IMKSLFLSTN MQERLRSKDR DLGSS
-
Molecular Weight
22 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interferon lambda (IFNλ) is a type of cytokine that plays a crucial role in the immune response against viral infections and has garnered significant interest in therapeutic applications. IFNλ is part of the type III interferon family, distinct from type I interferons (like IFNα and IFNβ) in terms of receptor usage and biological effects. Unlike type I interferons, IFNλ signals through a specific receptor complex consisting of IL-28R and IL-10R2, which confers unique regulatory properties. Research has demonstrated that IFNλ exhibits antiviral activity against a range of pathogens, including hepatitis viruses, and can modulate immune responses with potentially fewer side effects compared to type I interferons. This selectivity is particularly advantageous in developing treatments that minimize adverse reactions often associated with conventional interferon therapies. Furthermore, IFNλ's role in shaping adaptive immune responses provides avenues for its application in vaccination strategies and autoimmune diseases. Given its promising therapeutic potential, the recombinant production of IFNλ has become a focal point of biopharmaceutical research, leading to advancements in genetic engineering techniques. This effort aims to optimize yield, activity, and stability of the recombinant protein, facilitating further preclinical and clinical investigations. As a result, defining the mechanisms underlying IFNλ action and exploring its therapeutic utility continues to be an essential area of research, with the hope of developing novel treatments for viral infections, cancer, and immunological disorders.
